Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 37, Issue 10, 2018, Pages 1817-1827

  Taleb, Sara A ^a,b   Al Thani, Asmaa A ^a,b   Al Ansari, Khalid ^c   Yassine, Hadi M ^a,b  

^a Qatar University   (Qatar)

^b Qatar University   (Qatar)

^c HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Antibodies; Fusion glycoprotein; Pathogenesis; RSV; Vaccine

Indexed keywords

HOST FACTOR; MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN; VIRUS ANTIBODY; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENVIRONMENTAL FACTOR; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; NONHUMAN; PASSIVE IMMUNIZATION; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; THIRD TRIMESTER PREGNANCY; VACCINE IMMUNOGENICITY; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS; IMMUNOLOGY; METABOLISM; PATHOGENICITY; VACCINATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HUMANS; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINATION; VIRAL FUSION PROTEINS; VIRAL VACCINES;

EID: 85048061000     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-018-3289-4     Document Type: Review

References (101)

1. Rey-Jurado E, Kalergis AM (2017) Immunological features of respiratory syncytial virus-caused pneumonia—implications for vaccine design. Int J Mol Sci 18(3):556
2. Nair H et al (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725):1545–1555
3. Graham BS (2017) Vaccine development for respiratory syncytial virus. Curr Opin Virol 23:107–112
4. Widjaja I et al (2016) Characterization of epitope-specific anti-respiratory syncytial virus (anti-RSV) antibody responses after natural infection and after vaccination with formalin-inactivated RSV. J Virol 90(13):5965–5977
5. Varga SM, Braciale TJ (2013) The adaptive immune response to respiratory syncytial virus. Curr Top Microbiol Immunol 372:155–171
6. Sawadkohi RB et al (2012) Prevalence of acute lower respiratory tract infections due to respiratory syncytial virus in Amirkola Children’s Hospital, Northern Iran during March 2008–March 2010. Iran Red Crescent Med J 14(10):680
7. Collins PL (1991) The molecular biology of human respiratory syncytial virus (RSV) of the genus pneumovirus. In: Kingsbury DW (eds) The paramyxoviruses. The viruses. Springer, Boston
8. Collins PL et al (1986) Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc Natl Acad Sci 83(13):4594–4598
9. Graham BS, Modjarrad K, McLellan JS (2015) Novel antigens for RSV vaccines. Curr Opin Immunol 35:30–38
10. Tripp RA, Jorquera PA (2016) Human respiratory syncytial virus. Springer, Berlin
11. Kingsbury DW (2012) The paramyxoviruses. Springer Science & Business Media, Berlin
12. Li Y et al (2014) Inhibition of the human respiratory syncytial virus small hydrophobic protein and structural variations in a bicelle environment. J Virol 88(20):11899–11914
13. Barik S (2013) Respiratory syncytial virus mechanisms to interfere with type 1 interferons. Curr Top Microbiol Immunol 372:173–191
14. Chin V et al (2016) Design and validation of small interfering RNA on respiratory syncytial virus M2-2 gene: a potential approach in RNA interference on viral replication. J Virol Methods 236:117–125
15. Chamat S et al (1999) Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus—transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus. J Infect Dis 180(2):268–277
16. Fuentes S et al (2016) Antigenic fingerprinting following primary RSV infection in young children identifies novel antigenic sites and reveals unlinked evolution of human antibody repertoires to fusion and attachment glycoproteins. PLoS Pathog 12(4):e1005554
17. Mufson MA et al (1985) Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 66(10):2111–2124
18. Aamir UB et al (2013) Molecular characterization of circulating respiratory syncytial virus (RSV) genotypes in gilgit baltistan province of Pakistan during 2011-2012 winter season. PLoS One 8(9):e74018
19. Al-Toum R, Bdour S, Ayyash H (2006) Epidemiology and clinical characteristics of respiratory syncytial virus infections in Jordan. J Trop Pediatr 52(4):282–287
20. Turner TL et al (2014) Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res 6:217
21. Diseases CoI (2009) Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 124(6):1694–1701
22. Simoes EA (1999) Respiratory syncytial virus infection. Lancet 354(9181):847–852
23. Modjarrad K et al (2016) WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23–24 March 2015. Vaccine 34(2):190–197
24. Simões EA et al (2015) Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 211(suppl_1):S1–S20
25. Mousa JJ et al (2017) A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein. Nat Microbiol 2:16271
26. Magro M et al (2012) Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci 109(8):3089–3094
27. Ngwuta JO et al (2015) Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 7(309):309ra162–309ra162
28. Beeler JA, van Wyke Coelingh K (1989) Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63(7):2941–2950
29. McLellan JS et al (2013) Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340(6136):1113–1117
30. Krarup A et al (2015) A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun 6:8143
31. Gilman MS et al (2016) Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol 1(6). 10.1126/sciimmunol.aaj1879
32. Zhao X et al (2000) Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci 97(26):14172–14177
33. Tian D et al (2017) Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat Commun 8(1):1877
34. Graham BS (2016) Vaccines against respiratory syncytial virus: the time has finally come. Vaccine 34(30):3535–3541
35. Guzman E, Taylor G (2015) Immunology of bovine respiratory syncytial virus in calves. Mol Immunol 66(1):48–56
36. Wertz GW et al (1985) Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci 82(12):4075–4079
37. Openshaw PJ (2013) The mouse model of respiratory syncytial virus disease. Curr Top Microbiol Immunol 372:359–369
38. Ruckwardt TJ, Morabito KM, Graham BS (2016) Determinants of early life immune responses to RSV infection. Curr Opin Virol 16:151–157
39. Watkiss ER (2012) Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2(3):300–305
40. Johnson JE et al (2007) The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20(1):108–119
41. Wright PF et al (2005) Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J Virol 79(13):8651–8654
42. Wu W et al (2011) Characterization of the interaction between human respiratory syncytial virus and the cell cycle in continuous cell culture and primary human airway epithelial cells. J Virol 85(19):10300–10309
43. DeVincenzo JP et al (2010) Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 182(10):1305–1314
44. Moore ML et al (2009) A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 83(9):4185–4194
45. Stokes KL et al (2011) Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 85(12):5782–5793
46. Bitko V et al (2007) Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-κB-dependent, interferon-independent mechanism and facilitate virus growth. J Virol 81(4):1786–1795
47. Tripp RA et al (2001) CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2(8):732–738
48. Bukreyev A et al (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 82(24):12191–12204
49. Polack FP et al (2005) The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci U S A 102(25):8996–9001
50. Lukacs NW et al (2008) Regulation of immunity to respiratory syncytial virus by dendritic cells, toll-like receptors, and notch. Viral Immunol 21(2):115–122
51. Collins PL, Graham BS (2008) Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 82(5):2040–2055
52. Belderbos ME et al (2011) Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics 127(6):e1513–e1520
53. Miyairi I, DeVincenzo JP (2008) Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev 21(4):686–703
54. Knudson CJ et al (2015) RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog 11(3):e1004757
55. Littel-van den Hurk SV et al (2007) Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 17(1):5–34
56. Karr CJ et al (2009) Infant exposure to fine particulate matter and traffic and risk of hospitalization for RSV bronchiolitis in a region with lower ambient air pollution. Environ Res 109(3):321–327
57. Bradley JP et al (2005) Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics 115(1):e7–e14
58. Groskreutz DJ et al (2009) Cigarette smoke alters respiratory syncytial virus–induced apoptosis and replication. Am J Respir Cell Mol Biol 41(2):189–198
59. Evangelisti M et al (2015) Air pollution and bronchiolitis from 2004 to 2014 in Rome. Eur Respir J 46. 10.1183/13993003.congress-2015.PA4505
60. Gervassi AL, Horton H (2014) Is infant immunity actively suppressed or immature? Virology 5:1
61. Mold JE et al (2010) Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science 330(6011):1695–1699
62. Ndure J, Flanagan KL (2014) Targeting regulatory T cells to improve vaccine immunogenicity in early life. Front Microbiol 5:477
63. Dowling DJ, Levy O (2014) Ontogeny of early life immunity. Trends Immunol 35(7):299–310
64. Basha S, Surendran N, Pichichero M (2014) Immune responses in neonates. Expert Rev Clin Immunol 10(9):1171–1184
65. Cormier SA et al (2014) Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection. J Virol 88(16):9350–9360
66. Ruckwardt TJ et al (2014) Quantitative and qualitative deficits in neonatal lung-migratory dendritic cells impact the generation of the CD8+ T cell response. PLoS Pathog 10(2):e1003934
67. Marr N et al (2014) Attenuation of respiratory syncytial virus–induced and RIG-I–dependent type I IFN responses in human neonates and very young children. J Immunol 192(3):948–957
68. Malloy AM, Falsey AR, Ruckwardt TJ (2013) Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol 372:211–231
69. Iwasaki A, Medzhitov R (2015) Control of adaptive immunity by the innate immune system. Nat Immunol 16(4):343–353
70. Lambert L et al (2014) Immunity to RSV in early-life. Front Immunol 5:466
71. Karron RA, Buchholz UJ, Collins PL (2013) Live-attenuated respiratory syncytial virus vaccines. In: Anderson L, Graham B (eds) Challenges and opportunities for respiratory syncytial virus vaccines. Current Topics in Microbiology and Immunology, vol 372. Springer, Berlin, Heidelberg
72. Liu J et al (2016) A numerically subdominant CD8 T cell response to matrix protein of respiratory syncytial virus controls infection with limited immunopathology. PLoS Pathog 12(3):e1005486
73. Morabito KM et al (2017) Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. Mucosal Immunol 10(2):545–554
74. Welliver TP et al (2007) Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 195(8):1126–1136
75. Groothuis JR et al (1995) Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics 95(4):463–467
76. R., S.C.a.A (2009) B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 9(3):185–194
77. Sande CJ, Cane PA, Nokes DJ (2014) The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants. Vaccine 32(37):4726–4729
78. Zhang L et al (2002) Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 76(11):5654–5666
79. Hambling M (1964) Survival of the respiratory syncytial virus during storage under various conditions. Br J Exp Pathol 45(6):647
80. Killikelly AM, Kanekiyo M, Graham BS (2016) Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Sci Rep 6:34108
81. Johnson TR, McLellan JS, Graham BS (2012) Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. J Virol 86(3):1339–1347
82. Morris J, Blount R Jr, Savage R (1956) Recovery of cytopathogenic agent from chimpanzees with goryza. Proc Soc Exp Biol Med 92(3):544–549
83. KIM HW et al (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine 1 2. Am J Epidemiol 89(4):422–434
84. Murphy BR, Walsh EE (1988) Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26(8):1595–1597
85. Polack FP (2015) The changing landscape of respiratory syncytial virus. Vaccine 33(47):6473–6478
86. McLellan JS et al (2013) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342(6158):592–598
87. Moghaddam A et al (2006) A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12(8):905–907
88. Clemens R et al (1995) Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 171(Supplement_1):S44–S49
89. Furesz J, Scheifele DW, Palkonyay L (1995) Safety and effectiveness of the new inactivated hepatitis A virus vaccine. CMAJ 152(3):343
90. Zhao M et al (2017) Discovery of a prefusion RSV F-specific monoclonal antibody that provides greater in vivo protection than the murine precursor of Palivizumab. J Virol 91(15). 10.1128/JVI.00176-17
91. Gilman MS et al (2015) Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog 11(7):e1005035
92. Anderson L et al (2013) Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 31:B209–B215
93. Buchholz UJ et al (2018) Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children. J Infect Dis 217(9):1338–1346
94. Shah RR, Hassett KJ, Brito LA (2017) Overview of vaccine adjuvants: introduction, history, and current status. Methods Mol Biol 1494:1–13
95. Sastry M et al (2017) Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. PLoS One 12(10):e0186854
96. Falloon J et al (2016) A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine 34(25):2847–2854
97. Taylor G et al (2015) Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci Transl Med 7(300):300ra127–300ra127
98. Pardi N, Weissman D (2017) Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol Biol 1499:109–121
99. Liu X et al (2017) Attenuated human parainfluenza virus type 1 expressing the respiratory syncytial virus (RSV) fusion (F) glycoprotein from an added gene: effects of prefusion stabilization and packaging of RSV F. J Virol 91(22):e01101-17
100. Liang B et al (2017) Improved prefusion stability, optimized codon-usage, and augmented virion packaging enhance the immunogenicity of respiratory syncytial virus (RSV) fusion protein in a vectored vaccine candidate. J Virol 91(15). 10.1128/JVI.00189-17
101. Novavax. A study to determine the safety and efficacy of the RSV F vaccine to protect infants via maternal immunization. @ NIH clinical trial: https://clinicaltrials.gov/ct2/show/NCT02624947